We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Auto hematopoietic cell transplant not useful for mantle cell lymphoma with undetectable residual illness
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > Auto hematopoietic cell transplant not useful for mantle cell lymphoma with undetectable residual illness
Auto hematopoietic cell transplant not useful for mantle cell lymphoma with undetectable residual illness
Health

Auto hematopoietic cell transplant not useful for mantle cell lymphoma with undetectable residual illness

Last updated: December 7, 2024 12:01 pm
Editorial Board Published December 7, 2024
Share
SHARE

Autologous hematopoietic cell transplant (auto-HCT) is just not useful for sufferers with mantle cell lymphoma (MCL) in first full remission (CR) with undetectable minimal residual illness (uMRD), in keeping with a examine to be offered on the annual assembly of the American Society of Hematology, held from Dec. 7 to 10 in San Diego.

Timothy S. Fenske, M.D., from the Medical School of Wisconsin in Milwaukee, and colleagues carried out a four-arm trial involving sufferers with MCL between 18 and 70 years of age and in first remission. Sufferers in CR with uMRD at 1 in 10-6 sensitivity (uMRD6) have been randomly assigned to arm A (auto-HCT + three years of upkeep rituximab [MR]) or arm B (three years of MR alone). Sufferers with MRD-positive CR or MRD-indeterminate CR each acquired auto-HCT + three years of MR (arms C and D, respectively). The first finish level was to match survival in arms A and B.

From August 2017 to July 2024, 257, 259, 49, and 85 sufferers have been enrolled in arms A, B, C, and D, respectively. The researchers discovered that the estimated general survival hazard ratios for arms A and B in all randomized and treated-as-assigned sufferers (516 and 375, respectively) have been 1.11 (95% confidence interval, 0.71 to 1.74; P = 0.66) and 1.00 (95% confidence interval, 0.58 to 1.74; P = 0.99), and crossed the boundary for futility. Three-year general survival was 82.1 and 82.7%, respectively, for arms A and B in all randomly assigned sufferers, and 86.2 and 84.8%, respectively, in these handled as assigned.

“In this interim analysis, in the era of highly effective induction and maintenance regimens, MCL patients in first CR with uMRD6 did not benefit from consolidative auto-HCT,” the authors write.

A number of authors disclosed ties to the pharmaceutical and biotechnology industries.

© 2024 HealthDay. All rights reserved.

Quotation:
Auto hematopoietic cell transplant not useful for mantle cell lymphoma with undetectable residual illness (2024, December 6)
retrieved 7 December 2024
from https://medicalxpress.com/information/2024-12-auto-hematopoietic-cell-transplant-beneficial.html

This doc is topic to copyright. Aside from any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.

You Might Also Like

Alopecia areata related to extreme psychosocial influence

Intense, persistent grief linked to just about double mortality danger over 10 years

A media–public disconnect exists on wild meat narratives in central Africa throughout COVID-19

GLP-1 receptor agonist use linked to decrease mortality in seniors with most cancers, T2D

FDA upgrades recall on 160,000+ bottles of thyroid medicine

TAGGED:AutobeneficialcelldiseasehematopoieticLymphomamantleresidualtransplantundetectable
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Before Ukraine Invasion, Russia and China Cemented Economic Ties
Technology

Before Ukraine Invasion, Russia and China Cemented Economic Ties

Editorial Board February 26, 2022
Mike Lupica: Are these Yankees higher than the 2024 AL Champions?
‘Son of Elsewhere,’ a Funny and Frank Story About Life After a Big Move
Finding the Musical Spirit of Notre Dame
14 Easter Egg Hunt Concepts Good for Your Residence and Yard

You Might Also Like

Irritation and nutrition-based scores tied to prognosis of low-risk myelodysplastic syndrome
Health

Irritation and nutrition-based scores tied to prognosis of low-risk myelodysplastic syndrome

July 25, 2025
New research reveals essential hyperlink between neighborhood violence, youth preventing, and perceived firearm availability
Health

New research reveals essential hyperlink between neighborhood violence, youth preventing, and perceived firearm availability

July 25, 2025
Lengthy-term publicity to out of doors air air pollution linked to elevated threat of dementia
Health

Lengthy-term publicity to out of doors air air pollution linked to elevated threat of dementia

July 24, 2025
Analysis findings may enhance outcomes for critically in poor health sufferers on ventilators, examine finds
Health

Analysis findings may enhance outcomes for critically in poor health sufferers on ventilators, examine finds

July 24, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?